Goserelin

Generic Name: Goserelin

Brand Names: Zoladex

Drug Type: Small Molecule

Chemical Formula: C_₅₉H_₈₄N_₁₈O_₁₄

CAS Number: 65807-02-5

Unique Ingredient Identifier: 0F65R8P09N

Background: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...

Indication: Goserelin is indicated for:

Associated Conditions: Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate

Associated Therapies: Palliative Treatment

Clinical Trials

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2007-07-11

Last Posted Date: 2013-05-09

Lead Sponsor: University of Washington

Target Recruit Count: 1

Registration Number: NCT00498901

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer

Not Applicable

Conditions: Breast Cancer

First Posted Date: 2007-06-20

Last Posted Date: 2007-06-26

Lead Sponsor: Tianjin Medical University

Registration Number: NCT00488722

Locations: 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin, China

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: docetaxel
Drug: goserelin
Radiation: intensity-modulated radiation therapy

First Posted Date: 2007-06-05

Last Posted Date: 2023-11-24

Lead Sponsor: University of Nebraska

Target Recruit Count: 9

Registration Number: NCT00482807

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

Phase 1

Terminated

Conditions: Metabolic Syndrome

Interventions: Drug: Zoladex
Other: Placebo
Drug: Testosterone gel
Drug: Anastrozole Pill

First Posted Date: 2007-02-22

Last Posted Date: 2017-04-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 66

Registration Number: NCT00438321

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Exemestane
Drug: Cyclophosphamide
Drug: Goserelin
Drug: Docetaxel
Drug: Carboplatin

First Posted Date: 2007-02-07

Last Posted Date: 2023-04-03

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 189

Registration Number: NCT00432172

Locations: 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇪🇸
Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
🇪🇸
Centro Oncológico Regional de Galicia, A Coruña, Spain

and more 9 locations

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Goserelin

First Posted Date: 2007-01-31

Last Posted Date: 2016-05-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00429403

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇯🇵
St. Luke's International Hospital, Tokyo, Japan

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Radiation Therapy
Behavioral: Questionnaire
Drug: Bicalutamide
Drug: Leuprolide
Drug: Goserelin
Drug: Flutamide

First Posted Date: 2006-10-17

Last Posted Date: 2012-08-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00388804

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Testosterone Effects on Men With the Metabolic Syndrome

Phase 2

Withdrawn

Conditions: Metabolic Syndrome

First Posted Date: 2006-09-28

Last Posted Date: 2008-12-05

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 72

Registration Number: NCT00382057

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Phase 3

Completed

Conditions: Early-stage Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Goserelin
Drug: Tamoxifen
Drug: Methotrexate
Drug: Fluorouracil implant

First Posted Date: 2006-04-03

Last Posted Date: 2023-06-29

Lead Sponsor: Austrian Breast & Colorectal Cancer Study Group

Target Recruit Count: 1099

Registration Number: NCT00309478

Prostate Adenocarcinoma TransCutaneous Hormones

Phase 3

Conditions: Hot Flashes
Anemia
Osteoporosis
Prostate Cancer
Cardiovascular Complications

Interventions: Drug: Goserelin
Drug: Estradiol

First Posted Date: 2006-03-17

Last Posted Date: 2020-11-27

Lead Sponsor: University College, London

Target Recruit Count: 2200

Registration Number: NCT00303784

Locations: 🇬🇧
Walsgrave Hospital, Coventry, England, United Kingdom
🇬🇧
Mayday University Hospital, Croydon, England, United Kingdom
🇬🇧
Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom

and more 29 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy